Breakthrough technology enables high-resolution profiling of immune responses to allergens, microbes, and toxins—unlocking new frontiers in systems immunology and chronic disease research

Infinity Bio, the leader in antibody reactome profiling, is announcing the launch of EnviroSIGHT™, the world’s first comprehensive non-viral microbial and protein allergen antibody analysis service. This new offering provides an unprecedented capability to detail individuals’ immune responses to a vast array of environmental exposures, including pathogenic and opportunistic bacteria, diverse allergens (from plants, fungi, food, and arthropods), pathogenic and opportunistic fungi, the microbiome, parasites, and venom proteins. Environmental exposures sculpt the adaptive immune system, with important consequences across both infectious and chronic diseases.

“The EnviroSIGHT library completes our core antibody reactome service offerings,” said Dr. Ben Larman, founder and Chief Scientific Officer of Infinity Bio, and immunologist at Johns Hopkins University. Larman claims, “in combination with our pan-virome and pan-autoantibody libraries, VirSIGHT and HuSIGHT, our customers will now have access to the most comprehensive antibody assay ever developed – providing nearly one million antibody binding measurements at once.”

“EnviroSIGHT constitutes a significant advancement in systems immunology, enabling high-resolution, multiplexed profiling of antibody responses to an unparalleled breadth of environmental antigens. For the first time, we can interrogate, in a single assay, immune reactivity across pathogenic and commensal bacteria, fungi, parasites, microbiome constituents, allergens from multiple sources, and venom proteins. This comprehensive library opens new avenues for dissecting the immunological imprints of environmental exposures and their roles in infection, allergy, autoimmunity, and chronic inflammatory conditions,” said Dr. Eran Segal, member of Infinity Bio’s Scientific Advisory Board and Professor at the Weizmann Institute of Science and microbiome expert.

Infinity Bio’s proprietary antigen display technology MIPSA (Molecular Indexing of Proteins by Self-Assembly), developed in the Laboratory of Precision Immunology at Johns Hopkins, forms the foundation of this new service. MIPSA surpasses prior generation technologies like protein microarrays and phage display with enhanced sensitivity and specificity, and via improved library content and coverage. “EnviroSIGHT is a groundbreaking advancement in antibody research,” said Joy Nassif, CEO of Infinity Bio. “With our robust quality management systems, cutting-edge informatics pipelines, and a focus on customer satisfaction, researchers and pharmaceutical clients are benefiting from our services’ reliability, quick turnaround, and competitive pricing.”

EnviroSIGHT was designed by extracting protein sequences from the comprehensive Immune Epitope Database (IEDB), The ToxScan library, the Segal microbiome library, and all proteins from five allergen databases. This coverage of non-viral microbial antigens and allergens include:

• Pathogenic bacteria that cause diseases like strep throat, pneumonia, meningitis, Lyme disease and tuberculosis
• All known protein allergens from plants, fungi, food, and arthropods (including disease vectors)
• Beneficial components of the gut microbiome
• Parasites like toxoplasma, malaria, roundworms, and flatworms
• Pathogenic and opportunistic fungi
• Venom proteins from insects, arachnids and reptiles

“Unbiased antibody profiling with EnviroSIGHT will identify new causes of inflammation, provide valuable information for public health, and now in molecular detail, illuminate the specific microbial and allergen targets of aberrant immune responses,” says Dr. Katy Shaw-Saliba, Infinity Bio’s newly appointed Director of Scientific Development.

Currently available for research use only, EnviroSIGHT can be run alone or in combination with VirSIGHT and HuSIGHT. Applications span translational research, public health, biomarker discovery, and multi-omic cohort studies.

About Infinity Bio

Infinity Bio, Inc. is a technology company that provides detailed insights into the immune system using its proprietary antibody reactome profiling platform. The company's core technology, MIPSA, is used to reveal the targets of individual immune responses against all known human viruses, human proteins (autoimmunity), and allergen proteins. Developed at Johns Hopkins University in The Laboratory of Precision Immunology, MIPSA builds on decades of work in genomics, proteomics, immunology, and bioinformatics. Infinity Bio's assays are engineered to enable best-in-class quality, data accuracy, turnaround times and cost-efficiency. For more information, visit www.infinitybio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250715664058/en/